EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access

Prothrombin G20210A and Factor V Leiden Variants Are Not Associated With Thrombotic Events in Congenital Heart Disease: An Observational Trial

Feria A Ladha, Christina VanderPluym, Enrique Mondragon-Estrada iD, Paul Avillach iD, Martina Brueckner, Wendy K Chung iD, James F Cnota iD, Bruce D Gelb iD, Matthew Lewis iD, Cong Liu iD, Amy E Roberts iD, Christine E Seidman iD und 5 weitere

Journal of the American Heart Association · 17.03.2026 · 15 (6)

DOI: 10.1161/jaha.125.046959 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of the American Heart Association, erschienen am 17.03.2026. Verfasst von Feria A Ladha und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics Boston Children's Hospital Boston MA. Hauptthemen laut MEDLINE: Factor V, Prothrombin, Heart Defects, Congenital, Thrombosis. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Thrombotic events, including acute ischemic stroke, are more common in individuals with congenital heart disease (CHD). Whether common thrombophilia variants contribute to thrombotic risk in this population remains unclear. We evaluated whether prothrombin G20210A ( F2 c.97G>A) and factor V Leiden ( F5 c.1601G>A; p.Arg534Gln) are associated with thrombotic events in CHD.

Methods

Participants in the Pediatric Cardiac Genomics Consortium with exome sequencing and electronic medical record data were identified. Individuals were stratified by prothrombin G20210A and factor V Leiden genotypes, ventricular physiology, and antithrombotic therapy. The primary outcome was the presence of International Classification of Diseases ( ICD ) or Phecodes (phenotype codes) for thrombotic events.

Results

Among 4008 participants (median age, 11.4 [interquartile range, 5.1–17.9] years; 44.4% boys), thrombotic events occurred in 737 (18%), including 93 (13%) with acute ischemic stroke. Compared with the Genome Aggregation Database, the CHD cohort had a lower prevalence of heterozygous prothrombin G20210A and factor V Leiden variants. Variant prevalence did not differ between participants with and without thrombotic events. Single‐ventricle CHD was associated with higher thrombosis frequency than biventricular CHD (35% versus 16%, P ≤0.0001), without differences in variant prevalence.

Conclusions

In this multicenter CHD cohort, prothrombin G20210A and factor V Leiden were not significantly associated with thrombotic outcomes, supporting recommendations against routine screening. Given low variant prevalence, the study was powered to exclude only large associations. Reduced variant frequency suggests survivorship bias beginning in fetal life. Larger integrated clinical–genomic studies are needed to refine thrombotic risk stratification in CHD. Registration URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT03347214.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Factor VProthrombinHeart Defects, CongenitalThrombosisIschemic StrokeHumansMaleFemaleChildChild, PreschoolAdolescentRisk FactorsGenetic Predisposition to Disease

Stichwörter der Autor:innen

congenital heart diseasefactor V Leidenstrokethrombophiliathrombosis

Substanzen

Factor VProthrombinfactor V Leiden

Autor:innen und Institutionen

  • Department of Pediatrics Boston Children's Hospital Boston MA.
  • Department of Cardiology Boston Children's Hospital Boston MA.
  • Division of Newborn Medicine, Department of Pediatrics Boston Children's Hospital Boston MA.
  • Fetal Neonatal Neuroimaging and Developmental Science Center Boston Children's Hospital Boston MA.
  • Computational Health Informatics Program Boston Children's Hospital Boston MA.
  • Department of Pediatrics Harvard Medical School Boston MA.

ORCID-Profile: Enrique Mondragon-Estrada, Paul Avillach, Wendy K Chung, James F Cnota, Bruce D Gelb, Matthew Lewis, Cong Liu, Amy E Roberts, Christine E Seidman, Martin Tristani-Firouzi, Michael Wagner, Sarah U Morton, Jane W Newburger

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Ladha, F. A., VanderPluym, C., Mondragon-Estrada, E., Avillach, P., Brueckner, M., Chung, W. K., Cnota, J. F., Gelb, B. D., Lewis, M., Liu, C., Roberts, A. E., Seidman, C. E., Tristani-Firouzi, M., Wagner, M., Morton, S. U., Newburger, J. W., & Pediatric Cardiac Genomics Consortium Investigators (2026). Prothrombin G20210A and Factor V Leiden Variants Are Not Associated With Thrombotic Events in Congenital Heart Disease: An Observational Trial. Journal of the American Heart Association, 15(6). https://doi.org/10.1161/jaha.125.046959

Vancouver

Ladha FA, VanderPluym C, Mondragon-Estrada E, Avillach P, Brueckner M, Chung WK, et al. Prothrombin G20210A and Factor V Leiden Variants Are Not Associated With Thrombotic Events in Congenital Heart Disease: An Observational Trial. Journal of the American Heart Association. 2026;15(6). doi:10.1161/jaha.125.046959

BibTeX
@article{Ladha2026,
  author = {Ladha, Feria A and VanderPluym, Christina and Mondragon-Estrada, Enrique and Avillach, Paul and Brueckner, Martina and Chung, Wendy K and Cnota, James F and Gelb, Bruce D and Lewis, Matthew and Liu, Cong and Roberts, Amy E and Seidman, Christine E and Tristani-Firouzi, Martin and Wagner, Michael and Morton, Sarah U and Newburger, Jane W and Pediatric Cardiac Genomics Consortium Investigators, Pediatric Cardiac Genomics Consortium Investigators},
  title = {Prothrombin G20210A and Factor V Leiden Variants Are Not Associated With Thrombotic Events in Congenital Heart Disease: An Observational Trial},
  journal = {Journal of the American Heart Association},
  year = {2026},
  volume = {15},
  number = {6},
  doi = {10.1161/jaha.125.046959}
}
Kostenlos starten →